Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CODX Stock Forecast 2026-2027
$2.36
Current Price
$5.10M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CODX Price Targets
+1,806.8%
To High Target of $45.00
+1,806.8%
To Median Target of $45.00
+1,806.8%
To Low Target of $45.00
CODX Price Momentum
-61.4%
1 Week Change
-70.9%
1 Month Change
-89.4%
1 Year Change
-53.5%
Year-to-Date Change
-94.9%
From 52W High of $46.50
0.0%
From 52W Low of $2.36
📊 TOP ANALYST CALLS
Did CODX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Co-Diagnostics is one of their latest high-conviction picks.
Latest CODX Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, CODX has a neutral consensus with a median price target of $45.00 (ranging from $45.00 to $45.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.36, the median forecast implies a 1,806.8% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CODX Analyst Ratings
1
Buy
1
Hold
0
Sell
CODX Price Target Range
Low
$45.00
Average
$45.00
High
$45.00
Current: $2.36
Latest CODX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CODX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 26, 2025 | Maxim Group | Jason McCarthy | Buy | Initiates | $1.50 |
| Nov 24, 2025 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $N/A |
| Oct 28, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $3.00 |
| Oct 16, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $3.00 |
| Sep 19, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $3.00 |
| Sep 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Aug 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Apr 28, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $10.00 |
| Mar 28, 2025 | HC Wainwright & Co. | Yi Chen | Neutral | Maintains | $1.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $1.50 |
| Aug 12, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Maintains | $1.50 |
| Jun 17, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $2.00 |
| May 13, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Maintains | $2.00 |
| Mar 15, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Maintains | $2.50 |
| Dec 29, 2023 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $3.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Yi Chen | Neutral | Maintains | $3.00 |
| Aug 14, 2023 | HC Wainwright & Co. | Yi Chen | Neutral | Maintains | $2.00 |
| May 15, 2023 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $3.00 |
| Mar 20, 2023 | HC Wainwright & Co. | Yi Chen | Neutral | Downgrade | $3.00 |
| Feb 23, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $6.00 |
Co-Diagnostics Inc. (CODX) Competitors
The following stocks are similar to Co-Diagnostics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CODX
Co-Diagnostics
mkt cap
12.97M
Co-Diagnostics Inc. (CODX) Financial Data
Co-Diagnostics Inc. has a market capitalization of $5.10M with a P/E ratio of -0.1x. The company generates $507,892 in trailing twelve-month revenue with a 74.5% profit margin.
Revenue growth is -77.3% quarter-over-quarter, while maintaining an operating margin of -4,824.5% and return on equity of -62.1%.
Valuation Metrics
Market Cap
$5.10M
Enterprise Value
$2.17M
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
10.4x
Growth & Margins
Revenue Growth (YoY)
-77.3%
Gross Margin
+81.9%
Operating Margin
-4,824.5%
Net Margin
+74.5%
EPS Growth
-77.3%
Financial Health
Cash/Price Ratio
+238.9%
Current Ratio
3.8x
Debt/Equity
3.7x
ROE
-62.1%
ROA
-37.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Co-Diagnostics Inc. (CODX) Business Model
About Co-Diagnostics Inc.
What They Do
Develops innovative diagnostic technology for infectious diseases.
Business Model
Co-Diagnostics generates revenue by developing, manufacturing, and marketing diagnostic tests, particularly for infectious diseases like COVID-19 and Zika. Their proprietary CoPrimer™ technology enhances PCR test accuracy, allowing them to offer cost-effective and high-quality solutions.
Additional Information
Founded in 2013 and headquartered in Salt Lake City, Utah, the company plays a vital role in public health by improving access to essential diagnostic tools globally, particularly in resource-limited regions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
132
CEO
Mr. Dwight H. Egan
Country
United States
IPO Year
2017
Website
co-dx.comCo-Diagnostics Inc. (CODX) Latest News & Analysis
Latest News
Quick Summary
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its Indian joint venture, CoSara Diagnostics, is enhancing its distributor network in India after attending two regional conferences.
Why It Matters
Strengthening its distributor base in India enhances Co-Diagnostics' market presence and potential revenue growth, signaling positive prospects for investors in the company's future performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
16 days ago
Quick Summary
Co-Diagnostics, Inc. has received its first patent for its Co-Dx PCR platform from the Australian Patent Office, enhancing its intellectual property portfolio.
Why It Matters
The patent enhances Co-Diagnostics' competitive edge, potentially boosting market position and attracting investment, as it indicates innovation and exclusivity in molecular diagnostics.
Source: PRNewsWire
Market Sentiment:
Neutral
Co-Diagnostics Announces Reverse Stock Split
15 days ago
Quick Summary
Co-Diagnostics, Inc. has filed for a 1-for-30 reverse stock split, effective December 30, 2025. This will impact the company's common stock on the Nasdaq exchange.
Why It Matters
A 1-for-30 reverse stock split indicates Co-Diagnostics is attempting to boost its share price, which may affect liquidity and investor perception of the company's stability and growth potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CoDiagnostics has obtained its first patent for the Co-Dx PCR platform in Australia, enhancing its intellectual property protection while awaiting regulatory approval.
Why It Matters
Securing a patent enhances CoDiagnostics' competitive edge and potential market value, while regulatory clearance could lead to increased revenue from the Co-Dx PCR platform.
Source: Zacks Investment Research
Market Sentiment:
Negative
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
28 days ago
Quick Summary
Co-Diagnostics, Inc. announced an in silico analysis confirming the effectiveness of its Co-Primers® in the Logix Smart® ABC test for detecting influenza A, B, and COVID-19.
Why It Matters
Co-Diagnostics' successful analysis of its primers enhances confidence in its testing accuracy for influenza and COVID-19, potentially boosting demand and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Co-Diagnostics, Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd., will participate in a TB diagnostics workshop for South-East Asian countries.
Why It Matters
Co-Diagnostics' involvement in a TB diagnostics workshop signals growth potential and international collaboration, which may enhance revenue and market positioning, attracting investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CODX Stock
What is Co-Diagnostics Inc.'s (CODX) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Co-Diagnostics Inc. (CODX) has a median price target of $45.00. The highest price target is $45.00 and the lowest is $45.00.
Is CODX stock a good investment in 2026?
According to current analyst ratings, CODX has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CODX stock?
Wall Street analysts predict CODX stock could reach $45.00 in the next 12 months. This represents a 1,806.8% increase from the current price of $2.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Co-Diagnostics Inc.'s business model?
Co-Diagnostics generates revenue by developing, manufacturing, and marketing diagnostic tests, particularly for infectious diseases like COVID-19 and Zika. Their proprietary CoPrimer™ technology enhances PCR test accuracy, allowing them to offer cost-effective and high-quality solutions.
What is the highest forecasted price for CODX Co-Diagnostics Inc.?
The highest price target for CODX is $45.00 from at , which represents a 1,806.8% increase from the current price of $2.36.
What is the lowest forecasted price for CODX Co-Diagnostics Inc.?
The lowest price target for CODX is $45.00 from at , which represents a 1,806.8% increase from the current price of $2.36.
What is the overall CODX consensus from analysts for Co-Diagnostics Inc.?
The overall analyst consensus for CODX is neutral. Out of 5 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $45.00.
How accurate are CODX stock price projections?
Stock price projections, including those for Co-Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 14, 2026 3:24 AM UTC